Anika Therapeutics, Inc. (ANIK)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Anika Therapeutics, Inc. reported revenue of $112.82M, down 5.9% from the prior year. The company ran a net loss, with a net margin of -9.6% and a gross margin of 56.6%.
Key ratios (FY2025)
56.6%
Gross margin
-9.8%
Operating margin
-9.6%
Net margin
-7.6%
Return on equity
-5.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $112.82M | $119.91M | $120.79M | $113.83M | $147.79M | $130.46M | $114.61M | $105.56M | $113.42M | $103.38M |
| Cost of Revenue | $49.01M | $43.91M | $38.26M | $40.61M | $64.85M | $61.43M | $28.75M | $31.28M | $27.36M | $24.03M |
| Gross Profit | $63.81M | $76.00M | $82.53M | $73.22M | $82.94M | $69.03M | $85.86M | $74.28M | — | — |
| Operating Income | -$11.05M | -$5.10M | $844.0K | $3.67M | $2.62M | -$28.32M | $34.25M | $21.75M | $45.73M | $50.61M |
| Net Income | -$10.88M | -$56.38M | -$82.67M | -$14.86M | $4.13M | -$23.98M | $27.19M | $18.72M | $31.82M | $32.55M |
| EPS (Diluted) | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 | $-1.69 | $1.89 | $1.27 | $2.11 | $2.15 |
| Total Assets | $190.27M | $202.74M | $270.63M | $349.13M | $347.54M | $365.61M | $330.71M | $278.99M | $282.62M | $240.25M |
| Shareholders' Equity | $143.47M | $153.99M | $212.26M | $285.56M | $287.08M | $272.40M | $288.38M | $263.61M | $263.49M | $222.77M |
| Cash & Equivalents | $57.48M | $55.63M | $68.74M | $86.33M | $94.39M | $95.82M | $157.46M | $89.04M | $133.26M | $104.26M |
| Operating Cash Flow | $11.19M | $5.40M | -$1.79M | $4.41M | $8.40M | $13.06M | $37.01M | $34.92M | $40.81M | $24.45M |
| Capital Expenditures | $6.83M | $7.73M | $5.43M | $7.49M | $5.14M | $1.63M | $2.83M | $4.66M | $8.98M | $14.01M |
| Shares Outstanding | 14.34M | 14.72M | 14.66M | 14.79M | 14.63M | 14.22M | 14.37M | 14.69M | 15.07M | 15.12M |